← Leaderboards
Justin Michael Drake
Astrin Biosciences, Inc.
$1,931,918
Attributed
$2,131,757
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $840.4K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,131,757 · 2
By mechanism
R01$1,732,079 · 1
R41$399,678 · 1
Top collaborators
- Jayant Parthasarathy1 shared
Most similar at Astrin Biosciences, Inc.
Same institution · by research overlap
- Jayant Parthasarathy$199,839
Others in their field
Other Rising Stars on “Signal Pathway”
- Suma Babu · Massachusetts General Hospital$9,298,517
- Sabrina Paganoni · Massachusetts General Hospital$9,298,517
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
- Valentina Stosor · Northwestern University At Chicago$3,948,555
- Sarah Elizabeth Lutz · University Of Illinois At Chicago$3,350,409
Research focus
Signal PathwaySignal TransductionMutationSamplingTherapeutic TargetUnited StatesGenesMalignant NeoplasmsPathway InteractionsResistanceStandard Of CareTargeted TreatmentDrug TargetingTumorEnzalutamideGene ExpressionMalignant Neoplasm Of ProstateCancer EtiologyCessation Of LifeNeoplasm MetastasisCell SurvivalProstate Cancer TherapyAmericanBinding Sites
Grant awards (5)
RET Regulation and Targeting in Neuroendocrine Prostate Cancer$440,732
R01 · FY2025 · CA · contact PI
RET Regulation and Targeting in Neuroendocrine Prostate Cancer$418,696
R01 · FY2024 · CA · contact PI
RET Regulation and Targeting in Neuroendocrine Prostate Cancer$431,919
R01 · FY2023 · CA · contact PI
RET Regulation and Targeting in Neuroendocrine Prostate Cancer$440,732
R01 · FY2022 · CA · contact PI
Development of a novel personalized medicine platform using apheretically isolated circulating tumor cells to assess drug responsiveness in prostate cancer$399,678
R41 · FY2022 · CA